Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.06 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (nk-cells) | 0.10 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 77 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 4414
Sealed predictions
- XCL2 in dopamine neurons, braak+0.69 (p 0.039) → +0.61 (p 0.084)receipt 4421
Swarm cases
receipt 4421: XCL2 in dopamine neurons, braak
- power
- full sample +0.58 (p 0.012, n 18), 95% CI +0.15 to +0.82. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.55 (p 0.017, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.55 (p 0.017, n 18). not the mix.
- skeptic
- leave-one-out range +0.53 to +0.72, sign flips 0; without severely affected donors +0.58 (p 0.012, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for XCL2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts